Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

22 Jul 2016

Abstract excerpt

The constitutive activation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has been demonstrated to be critical in clinical cancer patients as well as in laboratory cancer models including hematological malignancies. Great efforts have been made to develop inhibitors targeting this pathway in hematological malignancies but so far the efficacies of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27583254
DOI: 10.21037/sci.2016.07.02

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?PMID 27583254Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

PI3K-Akt pathway: Its functions and alterations in human cancerSemantic proximity Read ↗

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Semantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.